147 related articles for article (PubMed ID: 38457884)
1. Metronomic radiological surveillance in clinically stable MS patients on anti CD20 immunotherapy is redundant.
Avasarala J
Mult Scler Relat Disord; 2024 May; 85():105541. PubMed ID: 38457884
[No Abstract] [Full Text] [Related]
2. Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.
Taupin P
Expert Opin Ther Pat; 2011 Jan; 21(1):111-4. PubMed ID: 21155688
[TBL] [Abstract][Full Text] [Related]
3. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
Frisch ES; Pretzsch R; Weber MS
Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland.
Airas L; Nylund M; Mannonen I; Matilainen M; Sucksdorff M; Rissanen E
Mult Scler Relat Disord; 2020 May; 40():101980. PubMed ID: 32066031
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in relapsing-remitting multiple sclerosis.
De Palma R; Sementa A
N Engl J Med; 2008 Jun; 358(24):2645-6; author reply 2646-7. PubMed ID: 18550883
[No Abstract] [Full Text] [Related]
6. Occasional essay: Multiple sclerosis in the digital age: 'seeing through a glass darkly'.
Compston A
J Neurol Neurosurg Psychiatry; 2020 Oct; 91(10):1017-1023. PubMed ID: 32709701
[No Abstract] [Full Text] [Related]
7. Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy.
Maillart E; Todesco E; Assoumou L; Beigneux Y; Lubetzki C; Papeix C; De Paz R; Dubessy AL; Djebara S; Louapre C; Pourcher V
J Neurol; 2024 May; 271(5):2871-2874. PubMed ID: 38212430
[No Abstract] [Full Text] [Related]
8. Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and management dilemmas.
Pfeuffer S
Mult Scler; 2024 Jun; 30(7):897-898. PubMed ID: 38385204
[No Abstract] [Full Text] [Related]
9. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis.
Bar-Or A; O'Brien SM; Sweeney ML; Fox EJ; Cohen JA
CNS Drugs; 2021 Sep; 35(9):985-997. PubMed ID: 34370283
[TBL] [Abstract][Full Text] [Related]
10. The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis.
Zhong M; van der Walt A; Campagna MP; Stankovich J; Butzkueven H; Jokubaitis V
Neurotherapeutics; 2020 Oct; 17(4):1768-1784. PubMed ID: 33058021
[TBL] [Abstract][Full Text] [Related]
11. An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis : Immunotherapy with rituximab, ocrelizumab, and ofatumumab.
Ovchinnikov A; Findling O
Wien Med Wochenschr; 2022 Nov; 172(15-16):359-364. PubMed ID: 35723820
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in relapsing-remitting multiple sclerosis.
Chaudhuri A; Behan PO
N Engl J Med; 2008 Jun; 358(24):2646; author reply 2646-7. PubMed ID: 18557178
[No Abstract] [Full Text] [Related]
13. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Hauser SL; Waubant E; Arnold DL; Vollmer T; Antel J; Fox RJ; Bar-Or A; Panzara M; Sarkar N; Agarwal S; Langer-Gould A; Smith CH;
N Engl J Med; 2008 Feb; 358(7):676-88. PubMed ID: 18272891
[TBL] [Abstract][Full Text] [Related]
14. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
de Flon P; Gunnarsson M; Laurell K; Söderström L; Birgander R; Lindqvist T; Krauss W; Dring A; Bergman J; Sundström P; Svenningsson A
Neurology; 2016 Jul; 87(2):141-7. PubMed ID: 27316241
[TBL] [Abstract][Full Text] [Related]
15. Ocrelizumab and Other CD20
Gelfand JM; Cree BAC; Hauser SL
Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in multiple sclerosis at general hospital level.
Hellgren J; Risedal A; Källén K
Acta Neurol Scand; 2020 Jun; 141(6):491-499. PubMed ID: 31990978
[TBL] [Abstract][Full Text] [Related]
17. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity.
Juto A; Fink K; Al Nimer F; Piehl F
Mult Scler Relat Disord; 2020 Jan; 37():101468. PubMed ID: 31683231
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the efficacy and safety of Zytux
Naser Moghadasi A; Darki A; Masoumi P; Hashemi SN; Ghadiri F
Mult Scler Relat Disord; 2019 Nov; 36():101419. PubMed ID: 31586800
[TBL] [Abstract][Full Text] [Related]
19. B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis.
Nissimov N; Hajiyeva Z; Torke S; Grondey K; Brück W; Häusser-Kinzel S; Weber MS
Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25690-25699. PubMed ID: 32999069
[TBL] [Abstract][Full Text] [Related]
20. The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
Topping J; Dobson R; Lapin S; Maslyanskiy A; Kropshofer H; Leppert D; Giovannoni G; Evdoshenko E
Mult Scler Relat Disord; 2016 Mar; 6():49-53. PubMed ID: 27063622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
